Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 164
Filter
Add more filters

Publication year range
1.
Osteoarthritis Cartilage ; 31(4): 458-466, 2023 04.
Article in English | MEDLINE | ID: mdl-36414224

ABSTRACT

OBJECTIVE: To review the current state of pharmaceutical treatment recommendations for the management of osteoarthritis. METHOD: A narrative review was drafted to describe treatment guidelines, mechanism of action, pharmacokinetics, and toxicity for nine classes of pharmaceuticals: 1) oral nonsteroidal anti-inflammatory drugs (NSAIDs), 2) topical NSAIDs, 3) COX-2 inhibitors, 4) duloxetine, 5) intra-articular corticosteroids, 6) intra-articular hyaluronic acid, 7) acetaminophen (paracetamol), 8) tramadol, and 9) capsaicin. RESULTS: In general, oral and topical NSAIDs, including COX-2 inhibitors, are strongly recommended first-line treatments for osteoarthritis due to their ability to improve pain and function but are associated with increased risks in patients with certain comorbidities (e.g., heightened cardiovascular risks). Intra-articular corticosteroid injections are generally recommended for osteoarthritis management and have relatively minor adverse effects. Other treatments, such as capsaicin, tramadol, and acetaminophen, are more controversial, and many updated guidelines offer differing recommendations. CONCLUSION: The pharmaceutical management of osteoarthritis is a constantly evolving field. Promising treatments are emerging, and medicines that were once considered conventional (e.g., acetaminophen) are gradually becoming less acceptable based on concerns with efficacy and safety. Clinicians need to consider the latest evidence and recommendations to make an informed decision with their patients about how to optimize treatment plans for patients with knee, hip, polyarticular, or hand osteoarthritis.


Subject(s)
Osteoarthritis, Knee , Tramadol , Humans , Osteoarthritis, Knee/drug therapy , Acetaminophen/therapeutic use , Tramadol/therapeutic use , Capsaicin/therapeutic use , Cyclooxygenase 2 Inhibitors/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Pharmaceutical Preparations
2.
Br J Anaesth ; 128(2): 363-374, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34916050

ABSTRACT

BACKGROUND: Postoperative pulmonary complications, including pneumonia, are a substantial cause of morbidity. We hypothesised that routine noninvasive respiratory support was associated with a lower incidence of pneumonia after surgery. METHODS: Systematic review and meta-analysis of RCTs comparing the routine use of continuous positive airway pressure (CPAP), noninvasive ventilation (NIV), or high-flow nasal oxygen (HFNO) against standard postoperative care in the adult population. We searched MEDLINE (PubMed), EMBASE, and CENTRAL from the start of indexing to July 27, 2021. Articles were reviewed and data extracted in duplicate, with discrepancies resolved by a senior investigator. The primary outcome was pneumonia, and the secondary outcome was postoperative pulmonary complications. We calculated risk difference (RD) with 95% confidence intervals using DerSimonian and Laird random effects models. We assessed risk of bias using the Cochrane risk of bias tool. RESULTS: From 18 513 records, we included 38 trials consisting of 9782 patients. Pneumonia occurred in 214/4403 (4.9%) patients receiving noninvasive respiratory support compared with 216/3937 (5.5%) receiving standard care (RD -0.01 [95% confidence interval: -0.02 to 0.00]; I2=8%; P=0.23). Postoperative pulmonary complications occurred in 393/1379 (28%) patients receiving noninvasive respiratory support compared with 280/902 (31%) receiving standard care (RD -0.11 [-0.23 to 0.01]; I2=79%; P=0.07). Subgroup analyses did not identify a benefit of CPAP, NIV, or HFNO in preventing pneumonia. Tests for publication bias suggest six unreported trials. CONCLUSION: The results of this evidence synthesis do not support the routine use of postoperative CPAP, NIV, or HFNO to prevent pneumonia after surgery in adults. CLINICAL TRIAL REGISTRATION: PROSPERO: CRD42019156741.


Subject(s)
Noninvasive Ventilation/methods , Pneumonia/prevention & control , Postoperative Complications/prevention & control , Adult , Continuous Positive Airway Pressure/methods , Elective Surgical Procedures/adverse effects , Elective Surgical Procedures/methods , Humans , Postoperative Complications/epidemiology , Postoperative Period , Randomized Controlled Trials as Topic
4.
PLoS Negl Trop Dis ; 17(5): e0011300, 2023 05.
Article in English | MEDLINE | ID: mdl-37126514

ABSTRACT

The risk of spillover of zoonotic diseases to humans is changing in response to multiple environmental and societal drivers, particularly in tropical regions where the burden of neglected zoonotic diseases is highest and land use change and forest conversion is occurring most rapidly. Neglected zoonotic diseases can have significant impacts on poor and marginalised populations in low-resource settings but ultimately receive less attention and funding for research and interventions. As such, effective control measures and interventions are often hindered by a limited ecological evidence base, which results in a limited understanding of epidemiologically relevant hosts or vectors and the processes that contribute to the maintenance of pathogens and spillover to humans. Here, we develop a generalisable next generation matrix modelling framework to better understand the transmission processes and hosts that have the greatest contribution to the maintenance of tick-borne diseases with the aim of improving the ecological evidence base and framing future research priorities for tick-borne diseases. Using this model we explore the relative contribution of different host groups and transmission routes to the maintenance of a neglected zoonotic tick-borne disease, Kyasanur Forest Disease Virus (KFD), in multiple habitat types. The results highlight the potential importance of transovarial transmission and small mammals and birds in maintaining this disease. This contradicts previous hypotheses that primates play an important role influencing the distribution of infected ticks. There is also a suggestion that risk could vary across different habitat types but currently more research is needed to evaluate this relationship. In light of these results, we outline the key knowledge gaps for this system and future research priorities that could inform effective interventions and control measures.


Subject(s)
Kyasanur Forest Disease , Tick-Borne Diseases , Ticks , Animals , Humans , Kyasanur Forest Disease/epidemiology , Tick-Borne Diseases/epidemiology , Zoonoses/epidemiology , India/epidemiology , Mammals
5.
Am J Transplant ; 11(12): 2613-26, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21883919

ABSTRACT

Virus-associated hematologic malignancies (EBV lymphoproliferative disease) and opportunistic infections (CMV) represent a major cause of hematopoietic stem cell and solid organ transplantation failure. Adoptive transfer of antigen-specific T lymphocytes appears to be a major and successful immunotherapeutic strategy, but improvements are needed to reliably produce high numbers of virus-specific T cells with appropriate requirements for adoptive immunotherapy that would allow extensive clinical use. Since plasmacytoid dendritic cells (pDCs) are crucial in launching antiviral responses, we investigated their capacity to elicit functional antiviral T-cell responses for adoptive cellular immunotherapy using a unique pDC line and antigens derived from Influenza, CMV and EBV viruses. Stimulation of peripheral blood mononuclear cells from HLA-A*0201(+) donors by HLA-A0201 matched pDCs pulsed with viral-derived peptides triggered high levels of multi-specific and functional cytotoxic T-cell responses (up to 99% tetramer(+) CD8 T cells) in vitro. Furthermore, the central/effector memory cytotoxic T cells elicited by the pDCs strongly display antiviral activity upon adoptive transfer into a humanized mouse model that mimics a virus-induced malignancy. We provide a simple and potent method to generate virus-specific CTL with the required properties for adoptive cellular immunotherapy of post-transplant diseases.


Subject(s)
Cytomegalovirus/immunology , Dendritic Cells/immunology , Herpesvirus 4, Human/immunology , Immunotherapy, Adoptive , Leukocytes, Mononuclear/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , CD8-Positive T-Lymphocytes/immunology , Cytomegalovirus Infections/immunology , Cytomegalovirus Infections/therapy , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/therapy , Female , HLA-A2 Antigen/immunology , Humans , Interferon-gamma/metabolism , Lymphocyte Activation , Lymphoproliferative Disorders/immunology , Lymphoproliferative Disorders/therapy , Male , Mice , Mice, Inbred NOD , Mice, SCID , Organ Transplantation/adverse effects , Postoperative Complications/immunology , Postoperative Complications/therapy , Vaccination , beta 2-Microglobulin/physiology
7.
Bioconjug Chem ; 21(1): 169-74, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20000459

ABSTRACT

Aptamers are known for their short in vivo circulating half-life and rapid renal clearance. Their conjugation to poly(ethylene glycol) (PEG) is a way to improve their residence in the body. Two aptamers (AptD and AptF), having a disulfide protected thiol modification on the 3' end, have been conjugated to maleimide activated PEGs of various molecular weights and structures (linear PEG20; branched PEG20 and 40; PolyPEG17, 40, and 60 kDa). The high yield coupling (70-80% in most of the cases) could be achieved using immobilized tris[2-carboxyethyl]phosphine hydrochloride (TCEP) as reducing agent at pH 4. The affinity of PEGylated AptD for its target was reduced by conjugation to linear PEG20 and branched PEG40, but not to branched PEG20 and PolyPEGs. This work demonstrates an alternative approach to PEGylation of aptamers, and that the effect of PEG on the affinity for the target varies according to the structure and conformation of the synthetic polymer.


Subject(s)
Aptamers, Nucleotide/chemistry , Drug Carriers/chemistry , Polyethylene Glycols/chemistry , Sulfhydryl Compounds/chemistry , Aptamers, Nucleotide/genetics , Aptamers, Nucleotide/metabolism , Aptamers, Nucleotide/pharmacokinetics , Binding Sites , Half-Life , Hydrogen-Ion Concentration , Kinetics , Maleimides/chemistry , Molecular Weight , Mucin-1/genetics , Phosphines/chemistry , Spectrometry, Fluorescence
9.
Anal Biochem ; 388(1): 91-6, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19233116

ABSTRACT

Mycothiol (MSH) is the principal low-molecular-weight thiol, unique to mycobacteria and other actinomycetes, that performs a role analogous to glutathione found in other organisms. MSH plays a key role in oxidative stress management and is oxidized to the dimeric mycothiol disulfide (MSSM) in the process. NADPH-dependent mycothiol disulfide reductase (Mtr) helps to maintain an intracellular reducing environment by reducing MSSM back to MSH. Mtr inhibition studies are currently impaired by limited availability of MSSM. Substrate demands are particularly high in time-dependent inhibition assays. Here we report an assay that chemically recycles a mixed disulfide substrate analogue in situ, thereby greatly reducing the substrate quantities needed for such assays. This has enabled the development of a continuous assay where linear reaction rates can be maintained for 40 min or longer using minimal substrate concentrations (5 microM versus a substrate K(m) value of 268 microM). In this manner, substrate requirements are reduced by orders of magnitude. Characterization of a novel time-dependent inhibitor, 2-(5-bromo-2-methoxyphenyl)acrylonitrile, is also demonstrated using these procedures.


Subject(s)
Enzyme Assays/methods , Enzyme Inhibitors/chemistry , NADH, NADPH Oxidoreductases/metabolism , Cysteine/chemistry , Glycopeptides/chemistry , Inositol/chemistry , Kinetics , NADH, NADPH Oxidoreductases/chemistry , NADH, NADPH Oxidoreductases/genetics , NADP/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Substrate Specificity , Sulfhydryl Compounds/chemistry , Time Factors
11.
Neuroscience ; 146(1): 160-9, 2007 Apr 25.
Article in English | MEDLINE | ID: mdl-17317017

ABSTRACT

Several studies have suggested that a potential mechanism for estrogen-mediated neuroprotection following experimental stroke is a result of modulating glutamate-mediated excitotoxicity. Our laboratory has shown that in male rats, estrogen injection (systemic or direct intracortical injection) resulted in an immediate depolarization of cortical neurons. Therefore, the present study was designed to investigate whether the estrogen-induced depolarization of cortical neurons was required in mediating the early events associated with this neuroprotection. We tested this hypothesis by co-injecting selective antagonists of the NMDA (MK-801) or AMPA (DNQX) glutamatergic receptors with estrogen. Systemic injection of estrogen significantly attenuated the MK-801-induced decrease in infarct volume following middle cerebral artery occlusion (MCAO). Similarly, when estrogen and MK-801 were co-injected directly into the cortex, no neuroprotection was observed. However, when estrogen or MK-801 was injected centrally 10 min prior to the injection of the other drug, significant neuroprotection was observed. This led us to hypothesize that estrogen-mediated neuroprotection required an initial activation of NMDA receptors. Furthermore, our results suggest that this estrogen-mediated neuroprotection was also associated with a significant increase in m-calpain and activation of an endoplasmic reticulum (ER) specific caspase-12. Finally, the results of current clamp experiments showed that estrogen significantly depolarized cortical neurons as well as enhanced NMDA-induced depolarization. Taken together, these results suggest that estrogen pretreatment may activate NMDA receptors resulting in modification of ER-associated molecular mechanisms involved in neuroprotection following MCAO.


Subject(s)
Cerebral Cortex/pathology , Estrogens/administration & dosage , Infarction, Middle Cerebral Artery/drug therapy , Neurons/pathology , Neuroprotective Agents/administration & dosage , Receptors, N-Methyl-D-Aspartate/physiology , Analysis of Variance , Animals , Blood Pressure/drug effects , Calpain/metabolism , Caspase 12/metabolism , Dizocilpine Maleate/pharmacology , Drug Interactions , Enzyme Activation/drug effects , Excitatory Amino Acid Agonists/pharmacology , Heart Rate/drug effects , In Vitro Techniques , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/physiopathology , Male , Membrane Potentials/drug effects , Neurons/drug effects , Patch-Clamp Techniques/methods , Quinoxalines/pharmacology , Rats , Rats, Sprague-Dawley
12.
Surgery ; 141(6): 715-22, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17560247

ABSTRACT

BACKGROUND: Although extensive study has been directed at the influence of patient factors and comorbidities on cardiac surgical outcomes, less attention has been focused on process. We sought to examine the relationship between intraoperative precursor events (those events that precede and are requisite for the occurrence of an adverse event) and adverse outcomes themselves. METHODS: Anonymous, prospectively collected intraoperative data was merged with database outcomes for 450 patients undergoing major adult cardiac operations. Precursor events were categorized by type, person most affected, severity, and compensation. Number and categories of precursor events were analyzed as predictors of a composite outcome combining death or near miss complications (DNM), using logistic regression. RESULTS: Precursor events occurred more frequently in cases with a DNM outcome than in those with no adverse event (2.7 +/- 2.4 vs 2.0 +/- 2.3/procedure, P = .005). After adjustment for other patient characteristics, the number of precursor events remained an independent predictor of DNM (RR, 1.14 per event [1.04 to 1.24]). Of 990 events, 35.6% related to management, 28.8% were technical, and 22.8% were environment-related. The surgeon was most affected in 40.8%, and 16.5% were of major severity. When categories of precursor events were analyzed, major severity events and those most affecting the surgeon were independent predictors of DNM. CONCLUSIONS: More detailed study of process in complex operations may lead to improved quality of care and patient safety. Special attention must be paid particularly to high risk patients and high risk precursor events.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Intraoperative Complications , Adult , Aged , Cardiac Surgical Procedures/mortality , Female , Humans , Intraoperative Period , Logistic Models , Male , Middle Aged , Risk Factors
13.
Mol Cell Biol ; 17(10): 5699-706, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9315628

ABSTRACT

Mutations in the p53 tumor suppressor gene frequently fall within the specific DNA-binding domain and prevent the molecule from transactivating normal targets. DNA-binding activity is regulated in vitro by metal ions and by redox conditions, but whether these factors also regulate p53 in vivo is unclear. To address this question, we have analyzed the effect of pyrrolidine dithiocarbamate (PDTC) on p53 DNA-binding activity in cell lines expressing wild-type p53. PDTC is commonly regarded as an antioxidant, but it can also bind and transport external copper ions into cells and thus exert either pro- or antioxidant effects in different situations. We report that PDTC, but not N-acetyl-L-cysteine, down-regulated the specific DNA-binding activity of p53. Loss of DNA binding correlated with disruption of the immunologically "wild-type" p53 conformation. Using different chelators to interfere with copper transport by PDTC, we found that bathocuproinedisulfonic acid (BCS), a non-cell-permeable chelator of Cu1+, prevented both copper import and p53 down-regulation. In contrast, 1,10-orthophenanthroline, a cell-permeable chelator of Cu2+, promoted the redox activity of copper and up-regulated p53 DNA-binding activity through a DNA damage-dependent pathway. We have previously reported that p53 protein binds copper in vitro in the form of Cu1+ (P. Hainaut, N. Rolley, M. Davies, and J. Milner, Oncogene 10:27-32, 1995). The data reported here indicate that intracellular levels and redox activity of copper are critical for p53 protein conformation and DNA-binding activity and suggest that copper ions may participate in the physiological control of p53 function.


Subject(s)
Antioxidants/pharmacology , Chelating Agents/pharmacology , Copper/metabolism , Protein Serine-Threonine Kinases , Thiocarbamates/pharmacology , Tumor Suppressor Protein p53/metabolism , Acetylcysteine/pharmacology , Ataxia Telangiectasia Mutated Proteins , Cell Cycle , Cell Cycle Proteins , Cell Line , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/biosynthesis , DNA/metabolism , DNA Damage , DNA-Binding Proteins , Humans , Hydrogen Peroxide/pharmacology , Intercalating Agents/pharmacology , Ion Transport/drug effects , Lipid Peroxidation , Oxidation-Reduction , Oxidative Stress , Phenanthrolines/pharmacology , Protein Binding/drug effects , Protein Conformation/drug effects , Proteins/physiology , Pyrrolidines/pharmacokinetics , Thiocarbamates/pharmacokinetics , Tumor Cells, Cultured , Tumor Suppressor Protein p53/biosynthesis , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/drug effects , Tumor Suppressor Proteins
14.
Diabetes Metab ; 33(1): 44-53, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17258921

ABSTRACT

AIMS: Pancreatic islets can be lost early following allotransplantation from oxidative stress. Antioxidant enzyme overexpression could confer a beneficial effect on islets exposed to reactive oxygen species (ROS) and nitrogen species. Here, we tested the effect of MnTMPyP, a superoxide dismutase/catalase mimetic. METHODS: INS-1 insulin-secreting cells or human islets were cultured with MnTMPyP and exposed to a superoxide donor (the hypoxanthine/xanthine oxidase (HX/XO) system), a nitric oxide donor [3-morpholinosydnonimine (SIN-1)] or menadione. Viability of INS-1 cells was assessed by WST-1 colorimetric assay and FACS analysis (Live/Dead test). ROS production was determined using fluorescent probes. Islet viability was estimated by WST-1 assay and endocrine function by static incubation. RESULTS: Following MnTMPyP treatment, ROS production in INS-1 cells was reduced by 4- to 20-fold upon HX/XO challenge and up to 2-fold upon SIN-1 stress. This phenomenon correlated with higher viability measured by WST-1 or Live/Dead test. MnTMPyP preserved islet viability upon exposure to SIN-1 or menadione but not upon an HX/XO challenge. Similarly, decrease in insulin secretion tended to be less pronounced in MnTMPyP-treated islets than in control islet when exposed to SIN-1, but no changes were noticed during an HX/XO stress. CONCLUSIONS: MnTMPyP was able to improve the viability of INS-1 cells and human islets exposed to oxidative challenges in vitro. Protection of INS-1 cells could be as high as 90%. This agent is therefore potentially attractive in situations involving the overproduction of ROS, such as islet transplantation.


Subject(s)
Islets of Langerhans/physiology , Metalloporphyrins/pharmacology , Oxidative Stress/drug effects , Animals , Cell Line , Cell Survival/drug effects , Humans , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/physiology , Islets of Langerhans/cytology , Islets of Langerhans/drug effects , Manganese , Rats , Reactive Oxygen Species/metabolism , Vasodilator Agents/pharmacology
15.
J Hand Surg Eur Vol ; 42(8): 823-826, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28707510

ABSTRACT

All patients (36 hands) with connective tissue disorders who underwent periarterial sympathectomy of the hand alone or in conjunction with vascular bypass at our institution between 1995-2013 were reviewed. The durable resolution of ulcers was significantly higher in patients treated by periarterial sympathectomy and bypass than in patients treated by periarterial sympathectomy alone. Although there were more digital amputations in patients treated by periarterial sympathectomy alone, the difference was not statistically significant. Vascular bypass in conjunction with sympathectomy may be better than sympathectomy alone in patients with digital ischaemia related to connective tissue disorders. LEVEL OF EVIDENCE: IV.


Subject(s)
Connective Tissue Diseases/complications , Connective Tissue Diseases/surgery , Fingers/blood supply , Ischemia/etiology , Ischemia/surgery , Sympathectomy , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Young Adult
16.
Leukemia ; 19(9): 1597-604, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16049516

ABSTRACT

Mesenchymal stem cells (MSC) have recently been used successfully in humans to control severe graft-versus-host disease. However, the mechanisms involved in their immunomodulatory effects remain a matter of debate. Here, we show that MSC are unable to activate allogeneic T cells even in the presence of T-cell growth factors. We then found that MSC inhibit T-cell proliferation triggered either by allogeneic, mitogenic or antigen-specific stimuli. Interestingly, MSC inhibit T-cell proliferation by inducing apoptosis of activated T cells, but have no effect on resting T cells. Furthermore, we show that this apoptosis could be related to the conversion of tryptophan into kynurenine by indoleamine 2,3-dioxygenase expressed by MSC in the presence of IFNgamma. Moreover, we show that the inhibitory effect of MSC is neither abrogated nor modified during expansion in culture or after irradiation. Together, these results bring new insight to the mechanisms of immunosuppression induced by MSC and might help to develop their clinical use controlling immune-related adverse effects in humans.


Subject(s)
Apoptosis/immunology , Mesenchymal Stem Cells/immunology , T-Lymphocytes/immunology , Cell Death/immunology , Humans , Interferon-gamma/pharmacology , Leukocytes, Mononuclear/immunology , Mesenchymal Stem Cells/enzymology , Tryptophan Oxygenase/biosynthesis , Tryptophan Oxygenase/immunology
17.
Eur J Cardiothorac Surg ; 29(4): 447-55, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16500109

ABSTRACT

OBJECTIVE: Increasing attention has been afforded to the ubiquity of medical error and associated adverse events in medicine. There remains little data on the frequency and nature of precursor events in cardiac surgery, and we sought to characterize this. METHODS: Detailed, anonymous information regarding intraoperative precursor events (which may result in adverse events) was collected prospectively from six key members of the operating team during 464 major adult cardiac surgical cases at three hospitals and were analyzed with univariable statistical methods. RESULTS: During 464 cardiac surgical procedures, 1627 reports of problematic precursor events were collected for an average of 3.5 and maximum of 26 per procedure. 73.3% of cases had at least one recorded event. One-third (33.3%) of events occurred prior to the first incision, and 31.2% of events occurred while on bypass. While 68.0% of events were regarded as minor in severity (e.g., delays and missing equipment), a substantial proportion (32.0%) was considered major and included anastomotic problems, pump failure, and drug errors. Most problems (90.4%) were reported as being compensated for, although many (30.9%) were never discussed among the team. Major events were more likely to be discussed (p<0.0001) and less likely to have been previously encountered (p=0.0005). Perceptions of the severity and compensation of events varied across the team, as did temporal patterns of reporting (p<0.0001). CONCLUSIONS: A wide range of problematic precursor events occurs during the majority of cardiac surgery procedures. Attention to causes and ways of preventing these precursor events could have an impact on the rate of significant errors and improve the safety of cardiac surgery.


Subject(s)
Cardiac Surgical Procedures , Intraoperative Complications/epidemiology , Medical Errors/statistics & numerical data , Adult , Analysis of Variance , Documentation/statistics & numerical data , Humans , Intraoperative Complications/prevention & control , Medical Errors/prevention & control , Postoperative Care/adverse effects , Preoperative Care/adverse effects , Prospective Studies , Risk Management/statistics & numerical data
18.
Harv Bus Rev ; 84(11): 106-13, 157, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17131567

ABSTRACT

On February 1, 2003, the world watched in horror as the Columbia space shuttle broke apart while reentering the earth's atmosphere, killing all seven astronauts. Some have argued that NASA's failure to respond with appropriate intensity to the so-called foam strike that led to the accident was evidence of irresponsible or incompetent management. The authors' research, however, suggests that NASA was exhibiting a natural, albeit unfortunate, pattern of behavior common in many organizations. The foam strike is a prime example of what the authors call an ambiguous threat-a signal that may or may not portend future harm. Ambiguous threats differ from threats with obvious causes-say, a fire in the building-for which the response is clear. They also differ from unmistakable threats that may lack straightforward response paths (such as the frightening oxygen-tank explosion aboard Apollo 13). However, when the warning sign is ambiguous and the threat's potential effect is unclear, managers may choose to ignore or discount the risk. Such an approach can be catastrophic. Firms that do a good job of dealing with ambiguous threats do not improvise during a crisis; rather, they apply a rigorous set of detection and response capabilities that they have developed and practiced beforehand. In this article, the authors outline how to put such capabilities in place long before a crisis strikes. First, companies need to hone their teamwork and rapid problem-solving skills through practice. Second, they must learn to recognize weak signals, amplify the threat, and encourage employees to ask disconcerting "what if" questions in a safe environment. Finally, they should explore possible responses to threats through quick, low-cost experimentation.


Subject(s)
Commerce/organization & administration , Risk Assessment/methods , United States
19.
Oncogene ; 19(46): 5227-36, 2000 Nov 02.
Article in English | MEDLINE | ID: mdl-11077439

ABSTRACT

The tumor suppressor p53 is a transcription factor which binds DNA through a structurally complex domain stabilized by a zinc atom. Zinc chelation disrupts the architecture of this domain, inducing the protein to adopt an immunological phenotype identical to that of many mutant forms of p53. In this report, we used 65Zn to show that incorporation of zinc within the protein was required for folding in the 'wild-type' conformation capable of specific DNA-binding. Using a cellular assay, we show that addition of extracellular zinc at concentrations within the physiological range (5 microM) was required for renaturation and reactivation of wild-type p53. Among other divalent metals tested (Cd2+, Cu2+, Co2+, Fe2+ and Ni2+), only Co2+ at 125 microM had a similar effect. Recombinant metallothionein (MT), a metal chelator protein, was found to modulate p53 conformation in vitro. In cultured cells, overexpression of MT by transfection could modulate p53 transcriptional activity. Taken together, these results suggest that zinc binding plays a regulatory role in the control of p53 folding and DNA-binding activity.


Subject(s)
Chelating Agents/pharmacology , Protein Folding , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/metabolism , Zinc/pharmacology , Animals , Cadmium/metabolism , Cadmium/pharmacology , Cations, Divalent/metabolism , Cations, Divalent/pharmacology , Cobalt/metabolism , Cobalt/pharmacology , DNA/genetics , DNA/metabolism , Ethylenediamines/pharmacology , Fibroblasts , Humans , Metallothionein/genetics , Metallothionein/metabolism , Metallothionein/pharmacology , Mice , Precipitin Tests , Protein Binding , Protein Conformation/drug effects , Protein Renaturation/drug effects , Thermodynamics , Transcriptional Activation/drug effects , Transfection , Tumor Cells, Cultured , Tumor Suppressor Protein p53/drug effects , Zinc/metabolism
20.
Oncogene ; 18(56): 8011-23, 1999 Dec 23.
Article in English | MEDLINE | ID: mdl-10637512

ABSTRACT

Simian Virus 40 Large T-antigen expressed in NIH3T3 cells increases p53 level and interacts with this tumor suppressor to form large nuclear complexes. We show here that T-antigen sensitizes NIH3T3 cells to low doses of the oxidative stress inducer menadione. This oxidant increased p53 accumulation and disrupted p53/T-antigen interaction, but not T-antigen/pRb, T-antigen/Hsc70 and p53/Hsc70 complexes; a phenomenon inhibited by the anti-oxidant N-acetyl-cysteine. Analysis of several p53 downstream gene products revealed that the level of Fas receptor, which was sharply reduced by T-antigen expression, was drastically increased in response to menadione treatment. Menadione also induced a T-antigen dependent cleavage of Fas ligand. Analysis performed with Fas receptor antagonist antibody and metalloproteinases inhibitor revealed that menadione triggers a Fas-dependent death of a fraction of T-antigen expressing cells. This Fas pathway does not activate caspase 8 or 3, probably because of the inhibition induced by T-antigen, and leads to a necrotic cell death which contributes at least in part to the hypersensitivity of T-antigen transformed cells to oxidative stress.


Subject(s)
Antigens, Polyomavirus Transforming/genetics , Antigens, Polyomavirus Transforming/metabolism , Apoptosis/physiology , Cell Transformation, Neoplastic , Oxidative Stress/physiology , Tumor Suppressor Protein p53/metabolism , fas Receptor/physiology , 3T3 Cells , Acetylcysteine/pharmacology , Animals , Antibodies/pharmacology , Antioxidants/pharmacology , Cell Survival/drug effects , Mice , Necrosis , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism , Simian virus 40/genetics , Vitamin K/pharmacology , fas Receptor/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL